Halozyme Therapeutics, Inc.

( )
HALO After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
IMMUImmunomedics, Inc. -0.32%85.2511.0%$715.31m
MRNAModerna, Inc. -0.04%70.520.0%$666.35m
AMGNAmgen, Inc. 0.51%248.301.3%$659.17m
ILMNIllumina, Inc. 0.01%305.503.5%$626.58m
NVAXNovavax, Inc. -2.91%107.9596.5%$605.28m
GILDGilead Sciences, Inc. -1.19%62.101.0%$578.27m
REGNRegeneron Pharmaceuticals, Inc. 0.30%573.612.7%$438.99m
BIIBBiogen, Inc. 0.11%282.351.6%$350.80m
VRTXVertex Pharmaceuticals, Inc. 0.96%270.311.9%$346.01m
SRNESorrento Therapeutics, Inc. 14.29%11.601.5%$320.77m
ALXNAlexion Pharmaceuticals, Inc. -0.74%112.462.0%$279.94m
EXASEXACT Sciences Corp. 2.32%102.0120.7%$271.56m
SGENSeattle Genetics, Inc. 0.24%190.966.0%$227.45m
VXRTVaxart, Inc. -2.50%6.830.0%$197.82m
MNTAMomenta Pharmaceuticals, Inc. 0.06%52.493.0%$177.06m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.